Efficacy of oxaliplatin in the treatment of colorectal cancer

ONCOLOGY

Volumn 14, Issue 12 SUPPL. 11, 2000, Pages 9-14

  Rothenberg, Mace L ^a,b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b Phase I Drug Development Program   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX;

CANCER STAGING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CLINICAL TRIALS, PHASE IV; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0034572294     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Advanced Colorectal Cancer Meta-Analysis Group: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10:896-903, 1992.
2. Advanced Colorectal Cancer Meta-Analysis Group: Meta-analysis of randomized trials testing the biochemical modulation of fluorou-racil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 12:960-969, 1994.
3. Meta-Analysis Group in Cancer: Efficacy of continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-Analysis Group in Cancer. J Clin Oncol 16:301-308, 1998.
4. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup Study. J Clin Oncol 15:808-815, 1997.
5. Saris CP, van de Vaart P, Rietbroek RC, et al: In vitro formation of DNA adducts by cisplatin, lobaplatin, and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17:2763-2769, 1996.
6. Mamenta EL, Poma EE, Kaufmann WK, et al: Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54:3500-3505, 1994.
7. Rixe O, Ortuzar W, Alvarez M, et al: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865, 1996.
8. Schmidt W, Chaney SG: Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799-805, 1993.
9. Raymond E, Faivre S, Woynarowski JM, et al: Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 25(2 suppl 5):4-12, 1998.
10. Raymond E, Buquet-Fagot C, Djelloul S, et al: Antitumor activity of oxaliplatin in combination with fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anticancer Drugs 8:876-885, 1997.
11. deBraud F, Munzone E, Nole F, et al: Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after fluorouracil. Am J Clin Oncol 21:279-283, 1998.